ID

15958

Description

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH); ODM derived from: https://clinicaltrials.gov/show/NCT02332590

Link

https://clinicaltrials.gov/show/NCT02332590

Keywords

Versions (1)
  1. 6/21/16 6/21/16 -
Uploaded on

June 21, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Rheumatoid Arthritis NCT02332590

English

Eligibility Rheumatoid Arthritis NCT02332590

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of rheumatoid arthritis ≥3 months duration. american college of rheumatology (acr) class i-iii functional status.
Description

Rheumatoid Arthritis | disease length

Data type

boolean

Alias
UMLS CUI [1]
C0003873
UMLS CUI [2]
C0872146
active ra defined as:
Description

Rheumatoid Arthritis Active

Data type

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0205177
at least 6 of 66 swollen joints and 8 of 68 tender joints,
Description

Joint swelling | Joint tenderness

Data type

boolean

Alias
UMLS CUI [1]
C0152031
UMLS CUI [2]
C0240094
high sensitivity c-reactive protein (hs-crp) ≥8 mg/l or esr ≥28 mm/h, and
Description

C-reactive protein; high sensitivity (hsCRP) | Erythrocyte sedimentation rate measurement

Data type

boolean

Alias
UMLS CUI [1]
C0973334
UMLS CUI [2]
C1176468
das28esr >5.1. patients who per investigator judgment were either intolerant of, or considered inappropriate candidates for continued treatment with methotrexate (mtx), or after at least 12 weeks of continuous treatment with mtx, or inadequate responders treated with an adequate mtx dose for at least 12 weeks.
Description

Disease activity score 28 joint in rheumatoid arthritis Erythrocyte sedimentation rate measurement | Medical contraindication Therapeutic procedure Methotrexate | Methotrexate Disease Response Inadequate

Data type

boolean

Alias
UMLS CUI [1,1]
C2732493
UMLS CUI [1,2]
C1176468
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0087111
UMLS CUI [2,3]
C0025677
UMLS CUI [3,1]
C0025677
UMLS CUI [3,2]
C1704632
UMLS CUI [3,3]
C0205412
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
age <18 years or the legal age of consent in the country of the study site, whichever is higher.
Description

Age | age subdivision of legal significance | Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0682055
UMLS CUI [3]
C0021430
current treatment with disease-modifying antirheumatic drug (dmards)/immunosuppressive agents including mtx, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine or hydroxychloroquine within 2 weeks prior to the baseline (randomization visit) or azathioprine, cyclophosphamide within 12 weeks prior to baseline (randomization visit) or leflunomide within 8 weeks prior to the randomization visit, or 4 weeks after cholestyramine washout.
Description

Therapeutic procedure Antirheumatic Drugs, Disease-Modifying | Therapeutic procedure Immunosuppressive Agents | Methotrexate | Cyclosporine | MYCOPHENOLATE | Tacrolimus | Gold | Penicillamine | Sulfasalazine | Hydroxychloroquine | Azathioprine | Cyclophosphamide | leflunomide | Cholestyramine Washout

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0242708
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0021081
UMLS CUI [3]
C0025677
UMLS CUI [4]
C0010592
UMLS CUI [5]
C0883242
UMLS CUI [6]
C0085149
UMLS CUI [7]
C0018026
UMLS CUI [8]
C0030817
UMLS CUI [9]
C0036078
UMLS CUI [10]
C0020336
UMLS CUI [11]
C0004482
UMLS CUI [12]
C0010583
UMLS CUI [13]
C0063041
UMLS CUI [14,1]
C0008402
UMLS CUI [14,2]
C1710661
treatment with any prior biologic agent, including anti-interleukin 6 (il-6), il-6 receptor (il-6r) antagonists, and prior treatment with a janus kinase inhibitor.
Description

Biological Agents Previous | Interleukin-6 Antagonist | Interleukin-6 Receptor Antagonist | Prior Therapy Janus kinase inhibitor

Data type

boolean

Alias
UMLS CUI [1,1]
C0005515
UMLS CUI [1,2]
C0205156
UMLS CUI [2]
C3864917
UMLS CUI [3]
C3819026
UMLS CUI [4,1]
C1514463
UMLS CUI [4,2]
C3854325
use of parenteral corticosteroids or intra-articular corticosteroids within 4 weeks prior to screening.
Description

Parenteral steroid treatment | intraarticular injection of corticosteroids

Data type

boolean

Alias
UMLS CUI [1]
C3840673
UMLS CUI [2]
C2064783
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
Back to the top of the page

Similar models

Eligibility Rheumatoid Arthritis NCT02332590

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis | disease length
Item
diagnosis of rheumatoid arthritis ≥3 months duration. american college of rheumatology (acr) class i-iii functional status.
boolean
C0003873 (UMLS CUI [1])
C0872146 (UMLS CUI [2])
Rheumatoid Arthritis Active
Item
active ra defined as:
boolean
C0003873 (UMLS CUI [1,1])
C0205177 (UMLS CUI [1,2])
Joint swelling | Joint tenderness
Item
at least 6 of 66 swollen joints and 8 of 68 tender joints,
boolean
C0152031 (UMLS CUI [1])
C0240094 (UMLS CUI [2])
C-reactive protein; high sensitivity (hsCRP) | Erythrocyte sedimentation rate measurement
Item
high sensitivity c-reactive protein (hs-crp) ≥8 mg/l or esr ≥28 mm/h, and
boolean
C0973334 (UMLS CUI [1])
C1176468 (UMLS CUI [2])
Disease activity score 28 joint in rheumatoid arthritis Erythrocyte sedimentation rate measurement | Medical contraindication Therapeutic procedure Methotrexate | Methotrexate Disease Response Inadequate
Item
das28esr >5.1. patients who per investigator judgment were either intolerant of, or considered inappropriate candidates for continued treatment with methotrexate (mtx), or after at least 12 weeks of continuous treatment with mtx, or inadequate responders treated with an adequate mtx dose for at least 12 weeks.
boolean
C2732493 (UMLS CUI [1,1])
C1176468 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0025677 (UMLS CUI [2,3])
C0025677 (UMLS CUI [3,1])
C1704632 (UMLS CUI [3,2])
C0205412 (UMLS CUI [3,3])
Item Group
C0680251 (UMLS CUI)
Age | age subdivision of legal significance | Informed Consent
Item
age <18 years or the legal age of consent in the country of the study site, whichever is higher.
boolean
C0001779 (UMLS CUI [1])
C0682055 (UMLS CUI [2])
C0021430 (UMLS CUI [3])
Therapeutic procedure Antirheumatic Drugs, Disease-Modifying | Therapeutic procedure Immunosuppressive Agents | Methotrexate | Cyclosporine | MYCOPHENOLATE | Tacrolimus | Gold | Penicillamine | Sulfasalazine | Hydroxychloroquine | Azathioprine | Cyclophosphamide | leflunomide | Cholestyramine Washout
Item
current treatment with disease-modifying antirheumatic drug (dmards)/immunosuppressive agents including mtx, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine or hydroxychloroquine within 2 weeks prior to the baseline (randomization visit) or azathioprine, cyclophosphamide within 12 weeks prior to baseline (randomization visit) or leflunomide within 8 weeks prior to the randomization visit, or 4 weeks after cholestyramine washout.
boolean
C0087111 (UMLS CUI [1,1])
C0242708 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0021081 (UMLS CUI [2,2])
C0025677 (UMLS CUI [3])
C0010592 (UMLS CUI [4])
C0883242 (UMLS CUI [5])
C0085149 (UMLS CUI [6])
C0018026 (UMLS CUI [7])
C0030817 (UMLS CUI [8])
C0036078 (UMLS CUI [9])
C0020336 (UMLS CUI [10])
C0004482 (UMLS CUI [11])
C0010583 (UMLS CUI [12])
C0063041 (UMLS CUI [13])
C0008402 (UMLS CUI [14,1])
C1710661 (UMLS CUI [14,2])
Biological Agents Previous | Interleukin-6 Antagonist | Interleukin-6 Receptor Antagonist | Prior Therapy Janus kinase inhibitor
Item
treatment with any prior biologic agent, including anti-interleukin 6 (il-6), il-6 receptor (il-6r) antagonists, and prior treatment with a janus kinase inhibitor.
boolean
C0005515 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C3864917 (UMLS CUI [2])
C3819026 (UMLS CUI [3])
C1514463 (UMLS CUI [4,1])
C3854325 (UMLS CUI [4,2])
Parenteral steroid treatment | intraarticular injection of corticosteroids
Item
use of parenteral corticosteroids or intra-articular corticosteroids within 4 weeks prior to screening.
boolean
C3840673 (UMLS CUI [1])
C2064783 (UMLS CUI [2])
Study Subject Participation Status
Item
the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
boolean
C2348568 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial